Mawi DNA Technologies Announces Partnership with FUJIFILM
Mawi DNA Technologies (Mawi) has signed a distribution agreement with FUJIFILM Wako Pure Chemical Corporation, a leader in the biomedical industry, to deliver Mawi’s iSWAB biosampling technologies to Japan.
“The collaboration with FUJIFILM Wako to provide iSWAB Microbiome-EL sample collection tubes for molecular testing of COVID-19 by PCR and LAMP based assay allows us to offer a valuable solution in the Japanese market,” said Atsushi Yanai, Asia Pacific Business Development at Mawi. “Being able to offer the collection without the need for an RNA Extraction step complements the WAKO Genomics product range, a valuable solution in the Japanese market and to society.”
FUJIFILM will be an authorized agent and distributor for Mawi products in Japan to detect viruses such as COVID-19.
“We are extremely grateful for the opportunity to partner with FUJIFILM, a respected organization with access to key customers in the Japanese market,” added Jerome David, VP of Sales and Marketing at Mawi. “We are confident that this initial partnership around our iSWAB-Microbiome-EL technology for extraction-less detection of SARS-CoV-2 RNA in patient samples will lead to additional opportunities for our entire portfolio of biosample collection products.”
About FUJIFILM Wako Pure Chemical Corporation
FUJIFILM Wako Pure Chemical Corporation is a comprehensive laboratory chemicals manufacturer contributing to a number of cutting-edge research fields. Over time, the company has developed and manufactured high-quality products and expanded its businesses to include specialty chemicals and clinical diagnostic reagents. For more information, visit https://www.fujifilm.com/ffwk/en.
About Mawi DNA Technologies
Mawi DNA Technologies, founded in 2013, has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Mawi’s mission is to uphold sample integrity from anywhere in the world at room temperature, enabling true sample diversity across any geography or population segment. The company’s flagship product iSWAB-DNA is the only sample collection product on the market proven to produce a high quality DNA sample with low bacterial DNA content. Mawi also supplies products for collection of RNA, microbiome, intact cells, and whole blood. At Mawi, The Future of Biosampling is Here™. For more information, visit http://www.mawidna.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Susan Tellem, APR, RN, BSN
310-313-3444 x1, Susan@tellemgrodypr.com
Jerome David, VP of Sales and Marketing
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ricardo Signs a £2.3m Contract to Provide Technical Oversight for Taipei’s New Metro Route28.10.2021 01:01:00 CEST | Press release
Ricardo is pleased to announce it has been appointed by the Taipei City Government to provide Independent Verification and Validation (IV&V) services for Phase Two of the Wanda–Shulin line, a driverless metro route under construction in Taipei, Taiwan, for a total of £2.3M. Our teams will assess whether the electrical and mechanical sub-systems - including rolling stock, infrastructure, communications and power supply - and their interfaces with civil and track works meet the client’s required standards for functionality, quality and operational safety. A key responsibility will be ensuring that Phase Two, a mostly elevated 11km section that is due to open in 2028, will integrate seamlessly with Phase One, a 9.5km underground section that is expected to commence passenger service in 2025. The completed line, which will be known on the Taipei Metro network as the ‘Light Green’ line, will operate with driverless technology (Grade-of-Automation 4) throughout. Mr. Jan, Deputy Chief Enginee
KartRider: Drift Closed Beta Announced at Sony’s State of Play Event28.10.2021 00:10:00 CEST | Press release
The next entry in Nexon’s phenomenally successful KartRider racing franchise is almost here! Announced during today’s Sony State of Play event,cross-platform sensation KartRider: Drift will launch its Closed Beta beginning December 8, at 4pm Pacific, through December 15, ending at 5am Pacific. Access to the KartRider: Drift Closed Beta will be available for PC on Nexon’s launcher and Steam, in addition to being available to console players on Xbox One and, for the first time, PlayStation® 4. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027006157/en/ KartRider: Drift Closed Beta Announced at Sony’s State of Play Event (Graphic: Business Wire) Gearing up to deliver new thrills in the beloved Nexon racing franchise, KartRider: Drift offers unparalleled character and kart customization. Karts can be tailored as never before, allowing players to transform their rides to reflect their inner racing persona. To help make sure y
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors27.10.2021 18:46:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire GammaDelta Therapeutics Limited (“GammaDelta”), a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy. Through the acquisition, Takeda will obtain GammaDelta’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms, which includes both blood-derived and tissue-derived platforms, in addition to early-stage cell therapy programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005677/en/ “We’re committed to developing cell therapies that will have an impact on large segments of patients by focusing on off-the-shelf, allogeneic cell therapies that are highly accessible and have the potential to address solid tumors. Collaborating with scientific innovators with unique technology platforms and deep domain expertise, such as the GammaDelt
FiRa Consortium Hits Major Milestones in Ultra-Wideband Momentum27.10.2021 18:00:00 CEST | Press release
The FiRa™ Consortium, a catalyst for bringing leading innovators together to drive Ultra-Wideband (UWB) expansion, is today announcing two milestones in the market acceptance of UWB technology. The first is the launch of the initial phase of its certification program aimed at driving interoperability between UWB devices. At the same time, FiRa Consortium is announcing it has now surpassed 100 members, including all of the top handset manufacturers globally, plus market leaders across semiconductors, networking, secure access, and consumer technology. “UWB is fast becoming a pillar of wireless local connectivity technology alongside Wi-Fi and Bluetooth,” said Charlie Zhang, Board Chair of FiRa Consortium. “When combined with the membership momentum we are seeing, our certification program signifies that the market is prepared and ready for broad implementation of UWB across market sectors.” FiRa Consortium’s certification program is the first to provide baseline testing and certificatio
Mitsubishi Corporation Life Sciences to Accelerate Next Wave of Digital Transformation and Business Growth by Switching to Rimini Street Support27.10.2021 18:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Mitsubishi Corporation Life Sciences, a food ingredients manufacturer within Mitsubishi Corporation’s Food Industry Group, has switched to Rimini Street Support for its JD Edwards applications. Switching from the vendor’s support to Rimini Street has enabled the company to dramatically reduce its maintenance costs and free up internal resources for strategic initiatives. By freeing up critical resources – time, money and personnel – Mitsubishi Corporation Life Sciences is able to begin investing in its digital transformation initiatives for the next five to 10 years and establish a foothold for further business expansion, both locally and overseas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005
CURACLE and Théa Announce Licensing and Collaboration Agreement for the Development and Commercialization of Orally Administered Treatment for Diabetic Macular Edema and Wet-AMD27.10.2021 17:47:00 CEST | Press release
CURACLE, a Korea-based biopharmaceutical company, today announced that it has entered into an exclusive license and collaboration agreement with Théa Open Innovation, the sister company of Théa, Europe’s number one independent ophthalmic company with a 150-year history, for the development and commercialization of CURACLE’s CU06-RE, that has the potential to become the first orally administered treatment for diabetic macular edema and wet age-related macular degeneration (wet-AMD). Under the terms of the agreement, CURACLE will receive an upfront payment of $6 million and could receive up to an additional $157.5 million in potential development, regulatory and sales milestones, as well as royalties on sales if CU06-RE is successfully developed, which will entitle CURACLE to receive up to $2 billion in total payments. Théa and CURACLE will closely collaborate on the clinical development of this novel oral drug. CURACLE will be responsible for the Phase I and II clinical studies with TOI
Everbridge Selected to Power the Nationwide Public Alert System for Spain27.10.2021 15:29:00 CEST | Press release
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM) and national Public Warning solutions, today announced the selection by Spain to deploy its next-generation population alerting technology to help keep the country’s more than 120 million residents and visitors safe and informed in case of an emergency. Everbridge announced the contract award anonymously in a press release last month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005638/en/ Everbridge Selected to Power the Nationwide Public Alert System for Spain (Graphic: Business Wire) The new country-wide public alert system of Spain will include both Cell Broadcast coverage at the national level, as well as the publication of alerts via the Web and through mobile alerts, powered by Everbridge. The state-of-the-art alert system will reach 99% of the population of Spain, including 47 million residents and nearly 80 million annual v